136 related articles for article (PubMed ID: 22082470)
21. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy.
Koh S; Sakai N; Maeda N; Nishida K
Acta Ophthalmol; 2018 Mar; 96(2):e255-e256. PubMed ID: 28834375
[No Abstract] [Full Text] [Related]
22. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.
Pisani A; Visciano B; Russo R; Mozzillo GR; Porto C; De Maggio I; Russo R; Pontarelli G; Villani GR; Cianciaruso B; Di Natale P
J Nephrol; 2012; 25(4):582-5. PubMed ID: 22307442
[TBL] [Abstract][Full Text] [Related]
23. [Priapism: a severe paediatric complication of Fabry disease].
Labarthe F; de Bodman C; Maruani A; Szwarc C; Froissart R; Lorette G; Lardy H
Rev Med Interne; 2010 Dec; 31 Suppl 2():S217-9. PubMed ID: 21211667
[TBL] [Abstract][Full Text] [Related]
24. Successful long-term enzyme replacement therapy in a young adult with Fabry disease.
Kampmann C; Kalkum G; Beck M; Whybra C
Clin Genet; 2013 Apr; 83(4):395-6. PubMed ID: 22881192
[No Abstract] [Full Text] [Related]
25. [Fabry disease. An interdisciplinary challenge].
Cybulla M; Neumann HP
Dtsch Med Wochenschr; 2007 Oct; 132(43):2271-7. PubMed ID: 17940933
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
Martin-Suárez I; Suárez-Marrero C
Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
[No Abstract] [Full Text] [Related]
27. [Management of Fabry disease].
Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
[TBL] [Abstract][Full Text] [Related]
28. Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.
Beer AM; Cooper-Knock J; Fletcher S; Brown-Wright SH; Nandakumar TP; Shaw PJ
Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):614-616. PubMed ID: 27094629
[No Abstract] [Full Text] [Related]
29. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
30. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
31. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
32. Pediatrics: implementing the promise of early intervention for Fabry disease.
Raas-Rothschild A
Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
[No Abstract] [Full Text] [Related]
33. Fabry disease: a treatable lysosomal storage disorder.
Phadke SR; Mandal K; Girisha KM
Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
[TBL] [Abstract][Full Text] [Related]
34. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Hughes DA; Nicholls K; Sunder-Plassmann G; Jovanovic A; Feldt-Rasmussen U; Schiffmann R; Giugliani R; Jain V; Viereck C; Castelli JP; Skuban N; Barth JA; Bichet DG
Am J Med Genet A; 2019 Jun; 179(6):1069-1073. PubMed ID: 30920142
[No Abstract] [Full Text] [Related]
35. Enzyme replacement therapy in Fabry disease in Poland: a position statement.
Nowicki M; Bazan-Socha S; Błażejewska-Hyzorek B; Gellert R; Imiela J; Kaźmierczak J; Kłopotowski M; Oko-Sarnowska Z; Pawlaczyk K; Ponikowski P; Sławek J; Sykut-Cegielska J; Witkowski A; Zwolińska D
Pol Arch Intern Med; 2020 Jan; 130(1):91-97. PubMed ID: 31868861
[No Abstract] [Full Text] [Related]
36. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
37. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
38. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
[TBL] [Abstract][Full Text] [Related]
39. Narrative review: Fabry disease.
Clarke JT
Ann Intern Med; 2007 Mar; 146(6):425-33. PubMed ID: 17371887
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Daidone M; Miceli S; Pinto A
Curr Pharm Des; 2020; 26(40):5089-5099. PubMed ID: 32183665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
